“Anti-PD-1 immune checkpoint blockade-based therapy using pembrolizumab in a patient with high-grade glioblastoma” (2023) Biomedical Research and Therapy, 10(5), pp. 5680–5685. doi:10.15419/bmrat.v10i5.809.